LegalApr 27, 2026, 07:02 AM
GSK: TESARO disputes AnaptysBio allegations on dostarlimab license
AI Summary
GSK plc and its subsidiary TESARO are involved in ongoing litigation with AnaptysBio concerning a license agreement for dostarlimab (Jemperli). AnaptysBio alleges TESARO has not fulfilled certain requirements of the March 2014 agreement and intends to revoke the license. GSK and TESARO firmly deny these allegations, viewing them as entirely without merit, and remain focused on pursuing their claim at trial. Jemperli is currently approved in over 35 countries for certain endometrial cancers and has reported significant growth, with an ambitious clinical trial program underway for additional cancer indications.
Key Highlights
- TESARO initiated litigation following AnaptysBio's allegations regarding the March 2014 license agreement for dostarlimab.
- AnaptysBio claims TESARO has not fulfilled certain license requirements and intends to revoke the dostarlimab license.
- GSK and TESARO firmly believe these allegations are without merit and are focused on pursuing their claim at trial.
- Jemperli (dostarlimab) is approved in over 35 countries for certain endometrial cancers.
- Significant growth for Jemperli has been reported due to label expansions in the US and EU.
- A robust clinical trial program for dostarlimab is ongoing to evaluate its use in additional cancers.